ELCC 2017: Latest News in Lung Cancer

Geneva, Switzerland, May 5-8 2017 – Around 2,000 delegates from across Europe and worldwide will learn about the latest practice-changing science in the field of thoracic oncology at the seventh European Lung Cancer Conference (ELCC) in Geneva, Switzerland, from 5 to 8 May 2017.

Key themes at this year’s meeting include some of the most topical and keenly anticipated subjects, pertinent not only to lung cancer but to oncology as a whole – such as the latest advances in immunotherapy and screening, new steps in the treatment of molecularly defined NSCLC and the new IASLC staging. Over 220 abstracts were submitted to the conference.

Organised by ESMO and the IASLC (International Association for the Study of Lung Cancer), along with their partner societies ESTRO (European Society for Radiotherapy & Oncology) and ETOP (European Thoracic Oncology Platform), this conference brings together some of the most important organisations representing thoracic oncology specialists. Having grown year-on-year, ELCC is today considered to be the point of reference in the field of thoracic malignancies, providing a truly groundbreaking multidisciplinary programme.

ESMO co-chair Martin Reck, Germany, said: “ELCC is a multi-professional and interdisciplinary meeting which aims to present the latest advances in lung cancer. Nearly all key investigators of major trials will be at ELCC and we hope attendees will use this unique opportunity to discuss the exciting developments in lung cancer. It is my personal intention and hope that my colleagues will leave the conference optimistic about the new treatments available for their patients. Of course, we will also discuss ongoing challenges such as timely diagnosis and personalised medicine.”

IASCL co-chair Andrew Nicholson, UK, said “ELCC is hosted jointly by ESMO and the IASLC ensuring we share the latest information and facilitate exchanges between healthcare professionals committed to treating lung cancer patients. We are especially excited about the outcome of the latest IASLC staging project and discussing its impact on patient management.”

Media is invited to join the leading thoracic oncologists as they gather for state-of-the-art education and the latest advances in lung cancer treatment at this unique event.

Key themes for ELCC 2017

  • Immunotherapy: first-line treatment, biomarkers and combination approaches
  • New steps in the treatment of molecularly defined NSCLC
  • SCLC and mesothelioma
  • Management and diagnosis of persistence in molecularly defined NSCLC
  • Management of brain metastases
  • New IASLC staging
  • ESMO recommendations for thoracic malignancies

Highlights

  • Late Breaking Abstracts and sessions will be announced in April
  • Optimal screening interval for detection of newly developed lung cancer: Comparison of sexual difference
  • Early limited-stage small-cell lung cancer: Sub-group analysis of the concurrent once-daily versus twice-daily radiotherapy (CONVERT) trial
  • Video-Assisted Thoracic Surgery (VATS) Lobectomy for Non-Small Cell Lung Cancer After Induction Chemotherapy: A Propensity Score-Matched Analysis on Behalf of the Italian VATS Group
  • First-line afatinib for advanced EGFRm+ NSCLC: analysis of long-term responders (LTRs) in the LUX-Lung (LL) 3, 6 and 7 trials
  • NSCLC patients harbouring a rare or complex EGFR mutation are more often smokers and might not benefit from first line TKI therapy
  • Circulating immune-profile as predictor of outcome in NSCLC patients treated with Nivolumab
  • Patient-reported symptoms and impact of treatment with osimertinib vs chemotherapy for advanced non-small-cell lung cancer
  • Response to salvage chemotherapy following exposure to PD-1/PD-L1 inhibitors in patients with NSCLC
  • Diagnostic EGFR Testing with ctDNA versus Tumour in patients with Advanced Non-Small Cell Lung Cancer (NSCLC): The Royal Marsden Experience.
  • Evaluation of non-classical response by immune-modified RECIST and efficacy of atezolizumab beyond disease progression in advanced NSCLC: results from the randomized Phase II study POPLAR
  • Immune response and adverse events to influenza vaccine in cancer patients undergoing PD-1 blockade
  • Validation of the prognostic value of 8th edition revisions of the AJCC staging system for non-small cell lung cancer; a SEER database analysis.
  • The impact of EGFR mutations on the prognosis of resected non-small cell lung cancer: A meta-analysis of literatures
  • The benchmark of examined lymph node count in node positive NSCLC patients: a populational validation with SEER database

The full conference programme is available at http://www.esmo.org/Conferences/ELCC-2017-Lung-Cancer/Programme

Media registration
Registration is free to bona fide journalists on presentation of a letter of assignment and a valid press card.

Media representatives are required to observe and abide by the ESMO Media Policy http://www.esmo.org/content/download/102361/1809327/file/ELCC-2017-Media-Policy.pdf

To register for the event, please fill out the Complimentary Media Registration Form http://www.esmo.org/Conferences/ELCC-2017-Lung-Cancer/Press-Media

Media registration in advance is strongly recommended, although on-site registration will still be possible.

Registered journalists can access all conference sessions and the ELCC Press Room.

Press Room opening hours

  • Friday, 05 May 2017: 09:00 – 18:00
  • Saturday, 06 May 2017: 08:00 – 18:00
  • Sunday, 07 May 2017: 08:00 – 18:00
  • Monday, 08 May 2017: 08:00 – 13:00

Embargo Policy

  • Abstracts accepted for presentation and for publication in the ELCC 2016 Abstract Book will be published online on the ELCC 2016 Web site on Wednesday, 26 April 2017 12:00 (CEST).
  • Abstracts selected for the official ELCC 2017 Press Programme (suffix _PR) will be made public starting on 26 April and at the latest at the start of the scientific session where they are being presented.

Journalists are required to observe embargoes as indicated, thank you!

About the European Lung Cancer Conference (ELCC)
The European Lung Cancer Conference (ELCC) has become the reference event in Europe for professionals treating lung cancers. From surgical resection to complex treatment options with novel agents and novel targets; from lung cancer in non-smokers to issues surrounding gender; from various forms of lung cancer, the big killer, to rare forms of chest tumors: the third edition of the ELCC will provide a comprehensive multidisciplinary overview of the latest as well as of the state-of-the-art knowledge in thoracic malignancies, covering different aspects such as prevention, screening, diagnosis, treatment modalities and the results of basic, clinical and translational research, presented by top international academic experts. Around 2000 attendees are expected from Europe and the rest of the world.

About the European Society for Medical Oncology (ESMO)
ESMO is the leading professional organisation for medical oncology. With more than 15,000 members representing oncology professionals from over 130 countries, ESMO is the society of reference for oncology education and information. We are committed to supporting our members to develop and advance in a fast-evolving professional environment.

ESMO’s educational resources support an integrated, multi-professional approach to cancer care. We have European roots and a global reach: we welcome oncology professionals from around the world and we seek to erase boundaries in cancer care as we pursue our mission across oncology, worldwide. www.esmo.org

About the International Association for the Study of Lung Cancer (IASLC)
The International Association for the Study of Lung Cancer (IASLC) is the only global organization dedicated to the study of lung cancer. Founded in 1974, the association’s membership includes more than 3,500 lung cancer specialists in 80 countries. To learn more about IASLC please visit www.iaslc.org

Media Contacts
ELCC Press Office
E-mail: media@esmo.org
Tel: +41 (0)91 973 19 04

Venue
Palexpo
30 Route François-Peyrot
1218 Le Grand-Saconnex
Geneva, Switzerland

Comments are closed.